Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Imugene Ltd (IMU.AX)

Imugene Ltd (IMU.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Imugene Ltd 4-6 Bligh Street Suite 12.01, Level 12 Sydney NSW 2000 AUS

https://www.imugene.com P: +61 294230881 F: +61 294230881

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

Key Statistics

Overview:

Market Capitalization, $K 82,814
Shares Outstanding, K 322,081
% of Institutional Shareholders 4.18%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -69,022 K

Growth:

1-Year Return -80.39%
3-Year Return -94.77%
5-Year Return -92.65%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.32
Dividend Payout Ratio 0.00%
Most Recent Split 1-34 on 07/02/25

IMU.AX Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -84.44%
Return-on-Assets % -58.19%
Profit Margin % 0.00%
Debt/Equity 0.06
Price/Sales N/A
Price/Book 1.84
Book Value/Share 0.14
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar